Category Archives: Market Access

Paying for the Future of Medicine

Is the hallmark of innovation higher drug prices? The three leading justifications for sticker-shocking drug prices in the US, from the biopharma perspective, are: 1) it costs a lot to bring a drug to market;* 2) drugs – even very expensive ones – are cheaper in the long run since they prevent complications, hospitalizations and […]
Also posted in Biotech, FDA, healthcare, leadership, Manufacturing, pricing, R&D, Regulatory, Technology | Tagged , , , , , , | 1 Comment

Eight Ingredients for a Successful Oncology Drug Development Recipe

by Matthew Cook and Sebastien Morisot In light of the risks and challenges inherent in the development of oncologics, some biopharma companies are beginning to question whether oncology remains an attractive therapeutic area in which to invest limited research, development, and commercialization resources.
Also posted in Agency Insight, Biotech, Europe, FDA, Gene therapy, Guest Blog, leadership, Orphan Drugs, pricing, R&D, Regulatory, Sales | Tagged , , | Leave a comment

Antibiotics Discovery: Time for a ‘Manhattan Project’

by Susan Crowley The innovative pharmaceutical industry is under attack from critics around the world for failing to develop new antibiotics to treat emerging infections. The charge has been furthered by statements from World Health Organization (WHO) director Margaret Chan. In 2012, she warned that bacteria were starting to become so resistant to common antibiotics […]
Also posted in Corporate Responsibility, Global, Guest Blog, healthcare, IP, leadership, Manufacturing, R&D, Strategy | Tagged , , , , , , , | 4 Comments

The US Biotech Drug Pricing Challenge

by Tom Norton In the midst of the hue and cry last week over the public release of individual Medicare payments to physicians, I was surprised to read that one of Medicare’s most costly medical services is — ophthalmology.  According to the New York Times: “One of the most heavily reimbursed procedures — costing a […]
Also posted in Biotech, Corporate Responsibility, Guest Blog, healthcare, pricing, Strategy | Tagged , , , , , , , , | 1 Comment

The Sovaldi Case: Is American Biotech History About to Repeat Itself?

Recent Congressional investigations over the pricing scheme of Gilead’s much-heralded hepatitis C drug Sovaldi – and a decline in stocks across the biotech sector – rings a familiar bell, writes Tom Norton. Twenty years ago in May, US Senator Joe Lieberman carefully questioned biotech CEO Harry Penner of then Neurogen Corporation about why his company’s […]
Also posted in Biotech, healthcare, leadership, pricing, R&D, Sales, Strategy | Tagged , , , , , , , , , | 2 Comments
  • Categories

  • Meta